Reportstack has announced a new market report on PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal. The Spanish influenza vaccine market is valued at approximately $33 million in 2012. The forecast drivers of growth include the launch of quadrivalent influenza vaccines and increase of the elderly population.
The market leader is trivalent Chiromas, Novartis’ adjuvanted influenza vaccine (marketed as Fluad in other countries). The adjuvant in this vaccine is designed to boost the immune response of elderly recipients, who often fail to be adequately protected by typical influenza vaccines. This improved immunogenicity has made Chiromas a popular selection among the elderly in Spain.
Scope
- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Spain from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Spain seasonal influenza market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in Spain.
The market leader is trivalent Chiromas, Novartis’ adjuvanted influenza vaccine (marketed as Fluad in other countries). The adjuvant in this vaccine is designed to boost the immune response of elderly recipients, who often fail to be adequately protected by typical influenza vaccines. This improved immunogenicity has made Chiromas a popular selection among the elderly in Spain.
Scope
- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Spain from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Spain seasonal influenza market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in Spain.
To view the table of contents and know more details please visit PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market Analysis report.
Similar Reports:
No comments:
Post a Comment